The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC

Autores
Categoría Estudio primario
Revistahttps://clinicaltrials.gov/show/NCT05862610
Año 2023
Trilaciclib indication: Trilaciclib, a CDK4/6 inhibitor, was used before chemotherapy to reduce the incidence of bone marrow suppression and approved by the FDA for small cell lung cancer patients in 2021.
Epistemonikos ID: 5e2d08a1e16842b0aa5ff1851401f7e52d4efdf2
First added on: Feb 19, 2024